Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TTV DNAemia
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Hospices Civils de Lyon
Deal Size : Inapplicable
Deal Type : Inapplicable
TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Virus-drug Conjugate
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : TTV DNAemia
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Hospices Civils de Lyon
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Hospices Civils de Lyon
Deal Size : Inapplicable
Deal Type : Inapplicable
Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 06, 2018
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Hospices Civils de Lyon
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Recipient : University Hospital, Geneva
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of the Lab-score on Antibiotic Prescription Rate in Children With Fever Without Source
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 01, 2014
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Recipient : University Hospital, Geneva
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyferon
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Radboud University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 05, 2011
Lead Product(s) : Polyferon
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Radboud University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable